NAYA Biosciences Inc is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Its portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a mode of action targeting non-responders to the current immunotherapy standard of care.
Revenue Compound Annual Growth Rate in the last 5 years.
Operating Income Compound Annual Growth Rate in the last 5 years.
Net Income Compound Annual Growth Rate in the last 5 years.
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
...and much more!